Drug costs for metastatic NSCLC stable, overall survival benefit poor

    This is a preview of subscription content, log in to check access.

    Reference

    1. Cramer-van der Welle CM, et al. Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. PharmacoEconomics-Open : 12 Jun 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00220-z

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Drug costs for metastatic NSCLC stable, overall survival benefit poor. PharmacoEcon Outcomes News 856, 14 (2020). https://doi.org/10.1007/s40274-020-6914-2

    Download citation